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Hematopoietic Stem Cell Mobilization With
Plerixafor Is Safe and Effective in Poorly
Mobilizing Acute Myeloid Leukemia Patients
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Autologous stem cell transplantation (ASCT) can be applied to
consolidate ﬁrst remission (CR1) in favorable/intermediate-risk
acute myeloid leukemia (AML) patients.1–2 However, up to 20%
of AML patients in CR1 fail to mobilize a sufﬁcient number of
peripheral blood stem cells (PBSC).3 We evaluated safety and
effectiveness of adding plerixafor to continued G-CSF stimula-
tion in 5 AMLpatients in CR1, who had failed tomobilize at least
10 CD34+ cells/mL in the peripheral blood. The patients received
a single dose of 24mg plerixafor intravenously 4 hours before
apheresis. Subsequent PBSC collection was successful in all
patients enabling them to proceed to ASCT, and all autografts
were molecularly minimal residual disease (MRD)-negative.
These data suggest that plerixafor added to G-CSF stimulation is
effective in AML patients with otherwise failing stem cell PBSC
mobilization.
In AML patients in CR1, high CD34+ cell counts harvested in a
single apheresis or high percentages of CD34+ cells in the
autografts are associated with adverse outcome.4 We and others
demonstrated that high numbers of peripheral circulating CD34+
cells at PBSC collection predicted higher relapse risk, whereas
delayed hematologic recovery after ASCT was associated with
better survival rates.5–8 Accordingly, a decreased mobilization
potential after induction chemotherapy can indicate a favorable
course in AML patients, in contrast to, for example, myeloma
patients undergoing high-dose chemotherapy (HDCT)/ASCT.5–7,9
Mobilization failure in AML patients in CR1 is so far poorly
studied, and subsequent alternative strategies are limited to bone
marrow (BM) harvesting with all its inconveniences. Moreover,
physicians are reluctant to use the rescue CXCR4 antagonist
plerixafor in AML patients given the possible mobilization of
residual leukemic stemcells and thepossibility toharvestmobilized
leukemic cells.10 However, this conclusion is not based on clinical
data in this situation. Accordingly,we investigated in this study the
safety and effectiveness of adding rescue plerixafor in AML
patients,which otherwisewould have failed stemcellmobilization.
We studied 5 patients with therapy-naïve de novo AML, who
received 2 cycles of induction chemotherapy at the University
Hospital of Bern. All patients had achieved CR after the ﬁrst
induction cycle and were planned for consolidation with HDCT/
ASCT based on their genetic risk proﬁles (Table 1). The second
induction cycle comprised cytarabine and daunorubicin in all
patients, and when BM assessment on day 18 conﬁrmed
remission, G-CSF was started on the ﬁrst day of neutrophils
rising >0.5G/L. Stem cell collection was planned on the ﬁrst day
of peripheral circulating CD34+ cells exceeding 20/mL. However,
all 5 patients failed to achieve at least 10/mL despite continued G-
CSF stimulation and were considered mobilization failure.
According to European Leukemia Net criteria, 4 patients had
favorable and 1 patient had intermediate risk.11 Four patients
showed mutations in the NPM1 gene, isolated in 1 case, or
combined with an FLT-ITD in 2 patients (in the ﬁrst one at a
high allele ratio of 0.5; and in the second one at a lower ratio of
0.39), or IDH1 (in 1 patient). The ﬁfth patient had biallelic
CEBPA mutations. All patients presented normal karyotypes.
The patient with high FLT3-ITD allelic ratio and NPM1
mutation underwent HDCT/ASCT due to primary biliary
cirrhosis making this patient ineligible for allogeneic HSCT.
MRD diagnostics were performed by real-time polymerase
chain reaction (PCR) for NPM1, fragment analysis for FLT3,
next-generation sequencing (NGS) for IDH1, and NGS and
Sanger sequencing for CEBPA. Molecular MRD analyses
indicated negativity both in the BM after second induction
before SC collection and in the autografts.
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The collection procedure in 3 patients was accomplished in a
single day following plerixafor administration, whereas 2
patients needed 2 consecutive apheresis days with plerixafor
given only at the ﬁrst day. The median number of circulating
peripheral CD34+ cells at the ﬁrst day of PBSC collection was 3.8
cells/mL (range 1.6–6.0) before plerixafor, and it was 24.9cells/
mL 4 hours after plerixafor administration. The median harvest
of collected CD34+ PBSC was 4.05106/kg (2.05–6.29),
respectively (Table 2).
All patients undergoing HDCT before ASCT received full-
dosed busulfan 4mg/kg per day p.o. (days 6 to 3) and
cyclophosphamide 60mg/kg per day i.v. (days 2/1), with
PBSC reinfusion at day 0. A median of 2.94106/kg b.w. CD34+
PBSC was transfused (2.06–4.30106/kg). Patients received a
median of 3 red blood cell transfusions and 4 platelet
transfusions. Neutrophils recovered >0.5G/L after a median
of 12 days (11–13 days), and the median time until platelets
increased >20G/L was 45 days (14–106 days). All patients
ultimately achieved complete hematologic recovery. The median
hospitalization duration was 24 days (21–36 days). After a
median follow-up of 14 months (9–17 months), all patients were
alive in ongoing CR1.
Whereas available data suggest that ASCT with PBSC can be
recommended to distinct subgroups of AML patients, there
is little information on the mobilization failure rate and on
rescue strategies for AML patients with a failed attempt of
autologous PBSC collection.12,13 In AML patients, chemo-
sensitivity of colony-forming units of granulocytes and mono-
cytes derived from BM cells were described to correlate inversely
with the peripheral maximum CD34+ cells peak during SC
mobilization.14
Plerixafor, a small-molecule inhibitor of the CXCR4 chemo-
kine receptor, has been approved in combination with G-CSF for
PBSC mobilization for lymphoma and myeloma patients.10
However, plerixafor is so far not recommended for PBSC
mobilization in AML patients due to the risk of mobilization of
leukemic cells and potential autograft contamination. We report
in this single-center study for the ﬁrst time the safe and successful
second-line mobilization of PBSC with plerixafor in AML
patients who failed conventional mobilization with G-CSF after
the second induction. Despite its limitations, our study suggests
that the rescue administration of plerixafor induced signiﬁcant
additional mobilization of CD34+ cells from the BM to the
peripheral blood, thereby allowing collecting sufﬁcient CD34+
cells in all 5 patients. In fact, the median number of circulating
peripheral CD34+ cells stimulated by G-CSF increased from 3.8
to 24.9106/L before and after plerixafor infusion. Conse-
quently, plerixafor administration enabled these patients
to proceed to subsequent consolidation with HDCT followed
by ASCT.
Due to the potential of plerixafor for comobilization of
leukemia stem cells,8 only MRD-negative patients combining
different molecular techniques (Table 1) were selected for
plerixafor application in this study, and MRD was excluded in
the autografts. Acknowledging these strict conditions, all
patients in this study maintained CR1 after a median follow-
up of 14 months. Importantly, our data are limited to AML
patients with MRD-negative CR1 in the BM and in the
autografts as candidates for plerixafor administration after
Table 2
Mobilization of Peripheral CD34+ Cells and Stem Cell Collection in
Acute Myeloid Leukemia Patients With Rescue Plerixafor Admin-
istration, Engraftment, Hospitalization, and Outcome
Mobilization and apheresis, n 5
Apheresis procedures, total number, n 7
Single day of apheresis, n (%) 3 (60)
Two days of apheresis, n (%) 2 (40)
Laboratory values, median (range)
WBC, at 1st day of apheresis, G/L 35.4 (12.1–63.6)
CD34+ cells, 106/L
in PB before plerixafor administration 3.8 (1.6–6.0)
in PB after plerixafor administration 24.9 (3.0–46.8)
Collected CD34+ cells/kg 4.05 (2.05–6.29)
Vitality of CD34+ cells, % 99 (97–99)
Transfused CD34+ cells/kg 2.94 (2.06–4.30)
Engraftment, median (range)
Red cells transfusions, n 3 (2–7)
Platelet transfusions, n 4 (1–8)
Neutrophil recovery (>0.5 G/L), d 12 (11–13)
Platelet recovery (>20 G/L), d 45 (14–106)
Hospitalization, d, median (range) 24 (21–36)
Outcome
Follow-up, mo, median (range) 14 (9–17)
Complete remission at last follow-up 5/5
Relapse during follow-up 0/5
PB = peripheral blood, WBC = white blood cells.
Table 1
Clinical and Disease Characteristics at Diagnosis of 5 AML
Patients With Imminent Mobilization Failure
Parameters n=5
Age, median, y (range) 59 (23–69)
Males:females 2:3
Laboratory values, median (range)
Hb, g/L 88 (63–107)
WBC, G/L 4.84 (1.3–26.3)
Peripheral blasts, % 15 (1–68)
Marrow blasts, % 80 (30–90)
Platelets, G/L 85 (26–138)
LDH, IU/L 712 (440–1512)
FAB classiﬁcation
M1 1
M2 2
M4 2
Cytogenetics
Normal karyotype 5
Mutation proﬁles
Mutated NPM1 only 1
Mutated NPM1, IDH1 1
Mutated NPM1, FLT3-ITD low 1
Mutated NPM1, FLT3-ITD high 1
Biallelic mutations of CEBPA 1
MRD diagnostics Technique/sensitivity at follow-up
Mutated NPM1, subtype A Real-time PCR (104 to 106)
Mutated IDH1 NGS (∼1%)
Mutated CEBPA NGS (∼1%)
Mutated FLT3-ITD Fragment analysis (5%)
ELN risk group (2017)
Favorable 4
Intermediate 1
WHO subtypes (2016)
AML with mutated NPM1 4
AML with biallelic mutations of CEBPA 1
AML = acute myeloid leukemia, ELN = European Leukemia Net, FAB = French-American-British, Hb
= hemoglobin, LDH = lactate dehydrogenase, MRD = minimal residual disease, NGS = next-
generation sequencing, PCR = polymerase chain reaction, WBC = white blood cells.
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mobilization failure with G-CSF. Molecular MRD techniques
should be comprehensive, including real-time PCR in the
case of appropriate mutations, fragment analysis, and,
increasingly, NGS.
Hematologic recovery after ASCT using plerixafor and G-
CSF stimulation for collection of CD34+ PBSC is of obvious
interest. Neutrophil recovery >0.5G/L after ASCT occurred
after a median of 12 days, and, thus, was identical as in a
previous large study in AML patients receiving G-CSF only.12
Platelet recovery >20G/L seemed prolonged in plerixafor
mobilized AML patients, with a median of 45 days versus 16
days in G-CSF-only mobilized patients in our previous
series.12 Possibly, this delayed platelet recovery in plerixafor
mobilized AML patients reﬂects the background of primary
mobilization failure and a poor stem cell pool in these
particular patients.
In conclusion, rescue mobilization of PBSCwith plerixafor was
highly effective and safe in our small series of AML patients with
primary mobilization failure. However, others have reported the
development of secondary myelodysplastic syndromes or AML
following rescue mobilization by plerixafor and subsequent
HDCT/ASCT in 5 out of 43 patients with lymphomas or multiple
myeloma after a median of 29 months after ASCT.15 Acknowl-
edging the fact that these patients were heavily pretreated with
80% of them having received more than 2 prior chemotherapeu-
tic regimens and with 20% having a history of previous
radiotherapy, the question may arise whether plerixafor or
rather the preceding intensive anticancer treatment truly
contributed to the development of myeloid malignancies in these
patients.15 Nevertheless, further studies should aim to better
characterize the potential of plerixafor for reliable and safe
PBSC mobilization combined with G-CSF in AML patients
planned for ASCT.
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